Delivery Order SPE2DE21D0005-SPE2D625F4EFC
- Not listed
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a delivery order valued at $3,400 on July 17, 2025, by the Defense Logistics Agency's Medical Supply Chain division. The delivery order, which carries a fixed-price contract type with economic price adjustment provisions, is for PURAPLY AM XT EF, a 5-layer fenestrated advanced wound care product. The contract does not utilize a set-aside designation, indicating Organogenesis competed as a standard...
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a delivery order valued at $2,479.90 by the Defense Logistics Agency's Medical Supply Chain division on September 23, 2025. The contract, which operates under a fixed-price arrangement with economic price adjustment provisions, is for the supply of APLIGRAF, an advanced wound care and tissue regeneration product. The delivery order is scheduled for completion by September 26, 2025, and was awarded...
- Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, was awarded a $17.82K delivery order on September 9, 2025, for PURAPLY SX 6CM x 9CM wound care dressings. This fixed-price contract with economic price adjustment carries an ultimate completion date of September 12, 2025, and is being funded through the Medical Supply Chain, a defense-oriented federal agency. The award was made on a competitive basis with no set-aside designation, reflecting...
- Organogenesis Inc., a Canton, Massachusetts-based regenerative medicine company, received a delivery order award valued at $1,239.95 from the Defense Logistics Agency's Medical Supply Chain for APLIGRAF, an advanced wound care and tissue regeneration product. The contract, awarded on May 7, 2025, carries a fixed price structure with economic price adjustment provisions and is scheduled for completion by May 12, 2025. No set-aside designation was used in this award, indicating Organogenesis...
- Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, has been awarded a delivery order by the Defense Logistics Agency (DLA) Medical Supply Chain for PURAPLY AM XT 4.91X4.91 wound care dressings. The fixed-price delivery order, valued at $11,580.00, was awarded on August 15, 2025, with an ultimate completion date of August 20, 2025. The contract carries no set-aside designation, allowing the company to compete as a standard commercial vendor. The place of...
- Organogenesis Inc. was awarded a $8,500 delivery order by the Defense Logistics Agency's Medical Supply Chain on July 23, 2025, for PURAPLY AM XT EF, a five-layer fenestrated advanced wound care product. The contract is structured as a fixed-price agreement with economic price adjustment provisions and is scheduled for completion by July 28, 2025. The work will be performed at Organogenesis' headquarters in Canton, Massachusetts. No set-aside designation was utilized for this award, indicating...
- Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, was awarded a delivery order valued at $1,239.95 for APLIGRAF, an advanced wound care and tissue regeneration product. The contract, awarded on May 30, 2025, with an ultimate completion date of June 4, 2025, utilizes fixed-price pricing with economic price adjustment terms. The award was made without a set-aside designation, indicating that Organogenesis competed as a standard commercial vendor. The...
- This is a fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts. The $1,504.00 contract is for the supply of PURAPLY MICRONIZED, 500MG, a specialized medical product used for advanced wound care. The award has an ultimate completion date of July 21, 2025. Organogenesis is a for-profit manufacturer that holds several significant federal Indefinite Delivery Vehicles (IDVs)...
- This $8,500 fixed-price delivery order was awarded to Organogenesis Inc., a regenerative medicine company, by the Defense Logistics Agency (DLA) Troop Support Medical on September 11, 2024. The order is for the supply of PURAPLY AM XT, a wound care product, with an ultimate completion date of September 16, 2024. Organogenesis is a key supplier of advanced wound care and surgical biologics products to the U.S. government, primarily serving the Department of Defense and Department of Veterans...
- The U.S. Defense Logistics Agency's Medical Supply Chain division awarded a $8,500 delivery order to Organogenesis Inc. on August 4, 2025, for PURAPLY AM XT EF 5-layer fenestrated wound care dressing. The contract is fixed-price with economic price adjustment and carries an ultimate completion date of August 7, 2025. The award was made without a set-aside designation, allowing Organogenesis to compete as a standard commercial vendor. Performance will take place at the company's headquarters in...
- SPE2DE21D0005Indefinite Delivery Contract
- SPE2DE21D0005-SPE2D625F4EFCDelivery Order
Organogenesis Inc., a Canton, Massachusetts-based regenerative medicine company, was awarded a delivery order valued at $1,504.00 by the Defense Logistics Agency's Medical Supply Chain division on September 25, 2025. The contract, classified as a fixed-price award with economic price adjustment provisions, calls for the delivery of PURAPLY Micronized 500mg and is scheduled for completion by September 30, 2025. No small business or other set-aside designation was utilized in this competitive award. This delivery order represents a continuation of Organogenesis's established role as a key supplier of advanced wound care and regenerative medicine products to the Department of Defense and other federal healthcare agencies. The company maintains several larger indefinite delivery vehicles that support such orders, including a $49.5 million multiple-award contract with DLA Troop Support Medical and substantial agreements with the Department of Veterans Affairs. PURAPLY Micronized, like other products in Organogenesis's portfolio, is utilized for advanced wound treatment and tissue regeneration to support military personnel and veteran healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 9/25/25 |